• The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program.
• The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform.
• VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies.
• The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting.
• VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered antibody formats.
• The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, signals progress as the biotechnology company prepares its most advanced BiTAC(R)-TCE candidate for future clinical development (https://ibn.fm/zBiDU).

Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

About BillionDollarClub

BillionDollarClub (“BDC”) is a specialized communications platform with a focus on the biggest and brightest companies covered by IBN. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BDC is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled recognition and brand awareness.

BDC is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BillionDollarClub, text “Billion” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: https://www.BillionDollarClub.com/Disclaimer

BillionDollarClub
Los Angeles, CA
www.BillionDollarClub.com
310.299.1717 Office
Editor@BillionDollarClub.com

BillionDollarClub is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany.